0001209191-12-007781.txt : 20120206 0001209191-12-007781.hdr.sgml : 20120206 20120206161345 ACCESSION NUMBER: 0001209191-12-007781 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120202 FILED AS OF DATE: 20120206 DATE AS OF CHANGE: 20120206 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Paul M CENTRAL INDEX KEY: 0001446372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 12573778 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0304 4 2012-02-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001446372 Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 0 1 0 0 SVP & Corp Controller Common Stock 2012-02-02 4 A 0 4500 0.01 A 13000 D Common Stock 1380 I 401(k) Stock Option 37.86 2012-02-02 4 A 0 18000 0.00 A 2012-05-02 2022-02-01 Common Stock 18000 18000 D Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Valerie L. Andrews, Attorney-In-Fact 2012-02-06